Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Leukocyte Adhesion Deficiency Syndrome
Interventions: Interferon gamma; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Immune Disorders
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndrome
Interventions: Vosaroxin; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Glioma
Interventions: Irinotecan (Camptosar, CPT-11); Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Cancer
Interventions: GA-driven Intervention; Other
Lead sponsor: University of Rochester; Other
Eligibility: 70 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Rochester, New York

Conditions: Corneal Endothelial Cell Loss
Interventions: Topcon Specular Microscope SP-1P, Konan Specular Microscope CELLCHEK XL; Device
Lead sponsor: Topcon Medical Systems, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Renal Failure
Interventions: LCP-Tacro tablets, Prograf; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions: Olezarsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 21
States / cities: Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more

Conditions: Tobacco Use Disorder
Interventions: Behavioral and pharmacologic tobacco use intervention; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Constipation
Interventions: polyethyleneglycol3350; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: Started 2003
U.S. locations: 45
States / cities: Hoover, Alabama • Mobile, Alabama • Pell City, Alabama + 38 more

Conditions: Venous Thromboembolism
Interventions: enoxaparin sodium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 4,726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sunitinib malate, gemcitabine hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Peripheral Arterial Disease
Interventions: Ischemic preconditioning, Control; Other
Lead sponsor: Center for Veterans Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Circulating Tumor Cells
Interventions: Blood draw; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Vaginal Vault Prolapse, Pelvic Organ Prolapse, Uterine Prolapse, Pelvic Floor Prolapse
Interventions: Preoperative Pessary Use; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Peripheral Neuropathy, HIV, AIDS, HIV Infections
Interventions: Acupuncture/Moxibustion; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: ASCVD, Elevated Cholesterol
Interventions: Inclisiran Sodium, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 145
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more

Conditions: Tobacco Dependence
Interventions: Nicotine free cigarettes, Extra-low nicotine cigarettes, Nicotine Lozenge; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atopic Dermatitis
Interventions: Etrasimod 1 mg, Etrasimod 2 mg, Etrasimod matching placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 35
States / cities: Tucson, Arizona • Canoga Park, California • Fountain Valley, California + 29 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 1356, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 24
States / cities: Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more

Conditions: Self-Regulation
Interventions: Daily weighing with daily feedback on weight, Weekly weighing with weekly feedback on weight; Other
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 29 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: bortezomib, dexamethasone, pegylated liposomal doxorubicin hydrochloride, thalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Elbow Fracture, Joint Contracture
Interventions: Synovial Fluid Analysis; Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I

A Phase 1 QT Study in Healthy Male Subjects

NIAID Clinical Center Genomics Opportunity Protocol

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy

Second Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Tobacco Use Intervention Among Radiation Oncology Patients

Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Cardiac Remote Ischemic Preconditioning Before Elective Major Vascular Surgery

Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy

Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use

Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Comparisons of Nicotine-free Cigarettes, Extra Low Nicotine Cigarettes vs. Medicinal Nicotine

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Diet, Physical Activity, and Weight Trends Study

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Synovial Fluid Analysis of Intraarticular Elbow Fracture